Catalent completes acquisition of MaSTherCell

By The Science Advisory Board staff writers

February 12, 2020 -- Catalent announced on February 11 that it has completed its acquisition of MaSTherCell Global, improving Catalent's position in the field of advanced biotherapeutics.

Catalent is a global clinical and commercial product development company that specializes in delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The addition of MaSTherCell's portfolio of technologies and analytical services in autologous and allogenic cell therapies will strengthen Catalent's position in the gene and cell therapy industry.

The acquisition includes MaSTherCell's 25,000-sq-ft clinical services facility in Belgium and its 32,000-sq-ft development-scale facility in Houston.

Catalent will also expand the construction of an already underway 60,000-sq-ft commercial-scale cell therapy production and fill-finish facility adjacent to the existing building in Belgium. This facility is set to open in the fall of 2021.

Catalent financed the acquisition with the proceeds of an underwritten public offering of its common stock completed last week.

Merck to build new biotech R&D center in Switzerland
Merck announced on January 27 an investment of 250 million euros ($275 million) to build a new biotech R&D center in Corsier-sur-Vevey, Switzerland.
Krystal expands commercial gene therapy production
Krystal Biotech on January 24 announced the beginning of construction on its second commercial gene therapy facility in Findlay Township in Pennsylvania....

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter